SpringWorks Therapeutics (SWTX) Competitors $37.44 -0.49 (-1.29%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SWTX vs. BEAM, VIR, CBPO, REPL, ALLO, PCVX, CTLT, SRPT, RVMD, and QGENShould you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Beam Therapeutics (BEAM), Vir Biotechnology (VIR), China Biologic Products (CBPO), Replimune Group (REPL), Allogene Therapeutics (ALLO), Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), and Qiagen (QGEN). These companies are all part of the "medical" sector. SpringWorks Therapeutics vs. Beam Therapeutics Vir Biotechnology China Biologic Products Replimune Group Allogene Therapeutics Vaxcyte Catalent Sarepta Therapeutics Revolution Medicines Qiagen Beam Therapeutics (NASDAQ:BEAM) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment. Which has stronger earnings and valuation, BEAM or SWTX? Beam Therapeutics has higher revenue and earnings than SpringWorks Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$377.71M5.37-$132.53M-$1.76-13.91SpringWorks Therapeutics$5.45M511.04-$325.10M-$3.88-9.65 Do insiders and institutionals hold more shares of BEAM or SWTX? 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.2% of Beam Therapeutics shares are owned by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor BEAM or SWTX? In the previous week, SpringWorks Therapeutics had 10 more articles in the media than Beam Therapeutics. MarketBeat recorded 15 mentions for SpringWorks Therapeutics and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.58 beat SpringWorks Therapeutics' score of 0.18 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SpringWorks Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, BEAM or SWTX? Beam Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Is BEAM or SWTX more profitable? Beam Therapeutics has a net margin of -41.07% compared to SpringWorks Therapeutics' net margin of -203.09%. Beam Therapeutics' return on equity of -16.22% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% SpringWorks Therapeutics -203.09%-48.21%-42.19% Does the MarketBeat Community believe in BEAM or SWTX? SpringWorks Therapeutics received 48 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 70.21% of users gave SpringWorks Therapeutics an outperform vote while only 54.26% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes5154.26% Underperform Votes4345.74% SpringWorks TherapeuticsOutperform Votes9970.21% Underperform Votes4229.79% Do analysts recommend BEAM or SWTX? Beam Therapeutics presently has a consensus target price of $44.91, indicating a potential upside of 83.38%. SpringWorks Therapeutics has a consensus target price of $67.00, indicating a potential upside of 78.95%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBeam Therapeutics beats SpringWorks Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SWTX vs. The Competition Export to ExcelMetricSpringWorks TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82B$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-9.6521.3797.3414.18Price / Sales511.04382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book5.234.195.805.12Net Income-$325.10M-$41.63M$119.07M$225.99M7 Day Performance2.44%-4.73%-1.83%-1.32%1 Month Performance22.79%-6.53%-3.64%0.60%1 Year Performance77.02%25.63%31.62%26.23% SpringWorks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SWTXSpringWorks Therapeutics2.0472 of 5 stars$37.44-1.3%$67.00+79.0%+68.5%$2.82B$5.45M-9.65305Analyst ForecastBEAMBeam Therapeutics2.9185 of 5 stars$24.49-3.2%$44.91+83.4%-20.4%$2.03B$377.71M-13.91461VIRVir Biotechnology3.019 of 5 stars$6.74-2.7%$36.40+440.1%-31.2%$954.40M$86.18M0.00587Analyst ForecastCBPOChina Biologic ProductsN/A$119.99+1.7%N/A+0.0%$4.72B$503.70M28.042,269REPLReplimune Group4.2366 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A0.00210ALLOAllogene Therapeutics2.7811 of 5 stars$2.05-3.3%$9.73+374.8%-31.4%$429.82M$90,000.00-1.31232Short Interest ↓PCVXVaxcyte3.2906 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900SRPTSarepta Therapeutics4.9373 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.64B88.691,314Analyst DowngradeGap UpRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.50B$11.58M0.00443QGENQiagen4.4347 of 5 stars$42.11+3.2%$50.88+20.8%+2.5%$9.31B$1.97B107.975,967Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Beam Therapeutics Competitors Vir Biotechnology Competitors China Biologic Products Competitors Replimune Group Competitors Allogene Therapeutics Competitors Vaxcyte Competitors Catalent Competitors Sarepta Therapeutics Competitors Revolution Medicines Competitors Qiagen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SWTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SWTX Stock Alerts